CN109937045A - 局部缺血/再灌注损伤 - Google Patents

局部缺血/再灌注损伤 Download PDF

Info

Publication number
CN109937045A
CN109937045A CN201780062730.6A CN201780062730A CN109937045A CN 109937045 A CN109937045 A CN 109937045A CN 201780062730 A CN201780062730 A CN 201780062730A CN 109937045 A CN109937045 A CN 109937045A
Authority
CN
China
Prior art keywords
bag3
ischemia
reperfusion injury
reperfusion
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780062730.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·M·费尔德曼
J·Y·查昂
K·哈利利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of CN109937045A publication Critical patent/CN109937045A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780062730.6A 2016-08-11 2017-08-10 局部缺血/再灌注损伤 Pending CN109937045A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662373410P 2016-08-11 2016-08-11
US62/373,410 2016-08-11
PCT/US2017/046237 WO2018031738A2 (en) 2016-08-11 2017-08-10 Ischemia/reperfusion injury

Publications (1)

Publication Number Publication Date
CN109937045A true CN109937045A (zh) 2019-06-25

Family

ID=61162527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062730.6A Pending CN109937045A (zh) 2016-08-11 2017-08-10 局部缺血/再灌注损伤

Country Status (10)

Country Link
US (2) US20190183971A1 (https=)
EP (1) EP3496726A4 (https=)
JP (1) JP7164885B2 (https=)
KR (2) KR20240130829A (https=)
CN (1) CN109937045A (https=)
AU (2) AU2017311405B2 (https=)
CA (1) CA3033633A1 (https=)
IL (2) IL264760B2 (https=)
MX (1) MX2019001729A (https=)
WO (1) WO2018031738A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438159A (zh) * 2019-07-03 2019-11-12 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN113502260A (zh) * 2021-07-16 2021-10-15 新疆医科大学第一附属医院 一种小鼠乳鼠原代心肌细胞分离与培养方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113082048B (zh) * 2021-05-08 2022-06-10 中国人民解放军陆军军医大学第二附属医院 一种Se@BSA纳米药物的制备方法及其在急性肾损伤中的应用
JP2025514489A (ja) * 2022-05-03 2025-05-02 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 脳におけるｂａｇ３およびタンパク質品質管理

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US20030175958A1 (en) * 2002-03-15 2003-09-18 Reed John C. Methods for using bag expression as a cell differentiation agent and marker
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
KR101436684B1 (ko) * 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIRGIT SAWITZKI 等: "Upregulation of Bag-1 by Ex Vivo Gene Transfer Protects Rat Livers from Ischemia/Reperfusion Injury", 《HUMAN GENE THERAPY》 *
JIANKAI ZHANG 等: "Overexpression of BAG3 Attenuates Hypoxia-Induced Cardiomyocyte Apoptosis by Inducing Autophagy", 《CELL PHYSIOL BIOCHEM》 *
MUN-YONG LEE 等: "Reactive Astrocytes Express Bis, a Bcl-2-Binding Protein, after Transient Forebrain Ischemia", 《EXPERIMENTAL NEUROLOGY》 *
YAYU MA 等: "Puerarin Attenuates Anoxia/Reoxygenation Injury Through Enhancing Bcl-2 Associated Athanogene 3 Expression, a Modulator of Apoptosis and Autophagy", 《MEDICAL SCIENCE MONITOR》 *
白玉花 等: "心肌缺血再灌注损伤模型建立方法的研究进展", 《内蒙古民族大学学报（自然科学版）》 *
阿迈·塔勒比 等: "心肌细胞缺氧/复氧损伤模型研究与应用进展", 《内蒙古中医药》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438159A (zh) * 2019-07-03 2019-11-12 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN110438159B (zh) * 2019-07-03 2023-02-28 广州中医药大学(广州中医药研究院) 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法
CN113502260A (zh) * 2021-07-16 2021-10-15 新疆医科大学第一附属医院 一种小鼠乳鼠原代心肌细胞分离与培养方法及其应用

Also Published As

Publication number Publication date
JP2019527736A (ja) 2019-10-03
IL264760B1 (en) 2023-03-01
AU2023237152B2 (en) 2026-01-22
EP3496726A4 (en) 2020-05-06
KR20240130829A (ko) 2024-08-29
KR20190042609A (ko) 2019-04-24
US20190183971A1 (en) 2019-06-20
IL300767A (en) 2023-04-01
CA3033633A1 (en) 2018-02-15
MX2019001729A (es) 2019-11-12
US20230390357A1 (en) 2023-12-07
AU2023237152A1 (en) 2023-10-19
JP7164885B2 (ja) 2022-11-02
IL264760B2 (en) 2023-07-01
IL264760A (https=) 2019-03-31
WO2018031738A2 (en) 2018-02-15
EP3496726A2 (en) 2019-06-19
IL300767B1 (en) 2026-03-01
AU2017311405B2 (en) 2023-07-13
AU2017311405A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2023237152B2 (en) Ischemia/Reperfusion injury
JP7834637B2 (ja) 治療用融合タンパク質
US20250001014A1 (en) Bag3 compositions and methods
CA2996975C (en) Methods for treatment of diseases
Ding et al. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1
JP7777986B2 (ja) 再灌流傷害の処置のためのｂｎｉｐ３ペプチド
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
CN108042791B (zh) 小分子多肽kp-1在制备治疗慢性肾脏病的药物中的用途
JP2019527736A5 (https=)
JP2016510596A (ja) ＰＴＤ−Ｓｍａｄ７薬物療法
US11560412B2 (en) Compositions comprising GRIM-19 therapeutics and methods of use
JP7824885B2 (ja) 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体
US12605398B2 (en) CRISPR-based compositions for treating vascular disorders
JP2019509731A (ja) 神経損傷を治療するペプチドベースの方法
WO2015033831A1 (ja) Ｄｐｐ－４を標的とした糖尿病治療用ワクチン
EP3275467A1 (en) Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome
HK40056903B (zh) 用於疾病治疗的方法
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
HK1258994B (zh) 用於疾病治疗的方法
JP2015214498A (ja) ホスファチジルセリンの細胞表面への表出促進剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination